header logo image


Page 371«..1020..370371372373..380390..»

Comprehensive Report on Animal Stem Cell Therapy Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | ANIMAL CELL THERAPIES,…

September 28th, 2020 4:54 pm

Animal Stem Cell Therapy Market research report is the new statistical data source added by A2Z Market Research.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

A complete analysis of Animal Stem Cell Therapy market is been done in this intelligence report. It includes the investigations done of the past progress, present ongoing market scenarios and future prospects. In this particular market report an accurate data of the products, strategies and market shares of leading companies are mentioned clearly.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=286567

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

ANIMAL CELL THERAPIES, Celavet, Animacel, VETSTEM BIOPHARMA, Cell Therapy Sciences, Magellan Stem Cells, Cells Power Japan, Animal Care Stem, Aratana Therapeutics, VetCell Therapeutics, MediVet Biologic, U.S. Stem Cell, J-ARM

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=286567

Global Animal Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

DogsHorsesOthers

Market Segmentation by Application:

Veterinary HospitalsResearch Organizations

The cost analysis of the Global Animal Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Table of Contents

Global Animal Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=286567

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Here is the original post:
Comprehensive Report on Animal Stem Cell Therapy Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | ANIMAL CELL THERAPIES,...

Read More...

Stem Cell Therapy Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis And Forecast To 2025 – The Daily Chronicle

September 28th, 2020 4:54 pm

Introduction: Global Stem Cell Therapy Market

Global Stem Cell Therapy Market Growth 2020-2025 has been updated by Adroit Market Research comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. The report provides a comprehensive study on growth drivers and notable trends impacting the future growth of the global Stem Cell Therapy market. The report highlights the complete assessment of the market and displays market sizing trends by revenue and volume, proficient opinions, current growth factors data, and industry-validated market development data. The analysts take a closer look at prominent opportunities, recent technological advances, and striking adoption trends in various nations. The study recognizes factors behind the growth of certain segments and focuses on emerging disruptive business models expected to create new revenue streams for market players.

Global Stem Cell Therapy market research report presentation demonstrates and presents an easily understandable market depiction, lending crucial insights on market size, market share as well as latest market developments and notable trends that collectively harness growth in the global Stem Cell Therapy market.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart): https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

Scope of the Report

This aforesaid Stem Cell Therapy market has noted a growth estimate of xx million US dollars in 2020 and is also likely to show favorable growth worth xx million US dollars through the forecast tenancy until 2025, clocking at an robust CAGR of xx% through the forecast period, 2020-25.

The report has included significant details about various facets covering manufacturer activities to offset the challenges prevalent during COVID-19.

The report in the following sections, emphasizes details on various market players, stakeholders, and participants. Details on upstream and downstream developments, production and consumption patterns are also addressed in the report to influence holistic and balanced growth in the global Stem Cell Therapy market.

Besides engaging in detailed analytical review of all the pertinent growth initiators impacting the global Stem Cell Therapy market, this immersive research report further focuses particular regional development episodes as well as also highlighting the country-specific changes that subsequently instill favorable growth outcome.

Additional details encompassing various development endeavors and new expansion considerations and dynamics alterations have all been addressed in the report that are known to encourage tremendous return on investments in global Stem Cell Therapy market.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

To Read More About the Report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Regional Analysis: Global Stem Cell Therapy Market

This intensive research report on global Stem Cell Therapy market also features significant highlights about various key developments across regions, also including details on country-wise developments.Additionally, the report draws attention on various market strategies business tactics and the like that various market participants are applying across regions to secure a healthy revenue trail in the global Stem Cell Therapy market.

Competitive Landscape: Global Stem Cell Therapy Market

1. This section of the report is designed to equip report readers with crucial details on the burgeoning developments in the competition spectrum, highlighting major developments across M&A investments by key market participants, notable commercial agreements as well as detailed product and service portfolio categorization to aid in successful business discretion.2. The report further shares crucial understanding on regional scope of the market with decisive detailing on regional and country-wise developments through the forecast span, 2020-27.

The report also includes discernable details on market scenario at the time of global pandemic based on sudden outrage of COVID-19. The report therefore is designed to serve as a requisite guide to initiate thoughtful marketing solutions to emerge successfully from the temporary dint caused by the pandemic.

5-Ponter Guide for Report Investment

A systematic and demonstrative assessment of core market segmentsA thorough evaluation of competition dynamics, market participants and intensityA systematic and methodological reference of major market events, inclusive also of the catastrophic developments in recent timesThe report in order to uphold real time market status is hovering mainly across important areas such as real time market growth status to encourage accurate market specific decisions,A pin-point review of core market developments, untapped market opportunities as well as market triggers, encapsulating crucial business strategies that effectively harness growth through the forecast span.The report also specifies vital details on vendor activities that aspiring players may direct to witness uncompromised growth.

Ask our Expert if You Have a Query at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

More here:
Stem Cell Therapy Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis And Forecast To 2025 - The Daily Chronicle

Read More...

Perinatal-Derived Exosomes are the Key to this Biotech’s Treatment Therapies – The Wall Street Transcript

September 28th, 2020 4:54 pm

September 25, 2020

Albert Mitranihas been Chief Operating Officer, President and board member at Organicell Regenerative Medicine, Inc. since April 2018, and he also is the Chairman of the board, Chief Executive Officer, Secretary and Treasurer at Organicell Regenerative Medicine, Inc. alternate name Biotech Products since June 24, 2011.

Mr. Mitrani formerly was the Chief Executive Officer, President and Director of Analytical Stem Cell Corp. from April 2014 to May 2015. From February 2012 to March 2014, he was the Chief Executive Officer of Americell Trinidad and the President of ASCAAC LLC American Stem Cell from March 2011 to January 2013. Mr. Mitrani was the Chief Executive Officer of American Cellular Center in Quito Ecuador from 2009 through 2012.

In this 2,511 word interview, exclusively in the Wall Street Transcript, Mr. Mitrani explains why investors should look at buying stock in his publicly traded company.

For several years, we have been doing a lot of research in various areas, specifically around lung diseases, and have collected data, more specifically around lung reparation.

When COVID hit, we came to the realization that through all of our work and expertise around regenerative therapeutics for the lungs, that there could be a potential opportunity for us to make a big difference in the treatment of this virus, particularly for patients with more severe lung injury and illness.

This particular treatment developed from some core stem cell therapy applications.

And with this knowledge of stem cells, we transitioned out of autologous stem cells and began searching for a regenerative therapy that would be more consistent. Particularly, something that we would be able to commercialize with reproducible and consistent effects.

Autologous stem cell therapies utilized autologous stem cells derived from the patients own blood. When you isolate these cells, the stem cell quality varies from patient to patient. The health of the stem cell population is largely dependent upon the patients health status and underlying conditions.

In our search for a better therapeutic source of cells for regenerative therapies, we ultimately focused on perinatal tissue

However, one component of paracrine factors that we found to be most promising for regenerative therapies were cell-secreted nanoparticles called exosomes and extracellular vesicles.

This type of therapy no longer requires the use of stem cells or cells. Our ability to identify and isolate these perinatal-derived exosomes is what really changed the direction of our company.

Get all the details on this potentially life changing drug discovery by reading the entire 2,511 word interview with Mr. Mitrani, exclusively in the Wall Street Transcript.

View post:
Perinatal-Derived Exosomes are the Key to this Biotech's Treatment Therapies - The Wall Street Transcript

Read More...

Cancer Stem Cell Therapy Market Size is Thriving worldwide with Topmost Companies Like: Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem…

September 28th, 2020 4:54 pm

Los Angeles, United State, The report titledGlobal Cancer Stem Cell Therapy Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cancer Stem Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cancer Stem Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cancer Stem Cell Therapy market is carefully analyzed and researched about by the market analysts.

Global Cancer Stem Cell Therapy Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Top Key Players of the Global Cancer Stem Cell Therapy Market: , AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem Cell Therapy

>>>Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528706/global-cancer-stem-cell-therapy-market

The Essential Content Covered in the Global Cancer Stem Cell Therapy Market Report :

Top Key Company Profiles.Main Business and Rival InformationSWOT Analysis and PESTEL AnalysisProduction, Sales, Revenue, Price and Gross MarginMarket Size And Growth RateCompany Market Share

Global Cancer Stem Cell Therapy Market Segmentation By Product:, Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Other Cancer Stem Cell Therapy

Global Cancer Stem Cell Therapy Market Segmentation By Application: , Hospital, Clinic, Medical Research Institution, Other

In terms of region, this research report covers almost all the major regions across the globe such asNorth America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. WhileCancer Stem Cell Therapy Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Cancer Stem Cell Therapy Market in South, America region is also expected to grow in near future.

Key questions answered in the report

*What will be the market size in terms of value and volume in the next five years?*Which segment is currently leading the market?*In which region will the market find its highest growth?*Which players will take the lead in the market?*What are the key drivers and restraints of the markets growth?

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Cancer Stem Cell Therapy market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

Why to Buy this Report?

Get Full Report in your inbox within 24 Hours athttps://www.qyresearch.com/settlement/pre/38d3cebd7b6edee6bb8a5e7082dfab14,0,1,global-cancer-stem-cell-therapy-market

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Cancer Stem Cell Therapy Revenue1.4 Market by Type1.4.1 Global Cancer Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Autologous Stem Cell Transplants1.4.3 Allogeneic Stem Cell Transplants1.4.4 Syngeneic Stem Cell Transplants1.4.5 Other1.5 Market by Application1.5.1 Global Cancer Stem Cell Therapy Market Share by Application: 2020 VS 20261.5.2 Hospital1.5.3 Clinic1.5.4 Medical Research Institution1.5.5 Other1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Cancer Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Cancer Stem Cell Therapy Growth Trends by Regions2.2.1 Cancer Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Cancer Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Cancer Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Cancer Stem Cell Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Cancer Stem Cell Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Cancer Stem Cell Therapy Players by Market Size3.1.1 Global Top Cancer Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Cancer Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Cancer Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Cancer Stem Cell Therapy Market Concentration Ratio3.2.1 Global Cancer Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Cancer Stem Cell Therapy Revenue in 20193.3 Cancer Stem Cell Therapy Key Players Head office and Area Served3.4 Key Players Cancer Stem Cell Therapy Product Solution and Service3.5 Date of Enter into Cancer Stem Cell Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Cancer Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Cancer Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Cancer Stem Cell Therapy Market Size by Application (2015-2020)5.2 Global Cancer Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Cancer Stem Cell Therapy Market Size (2015-2020)6.2 Cancer Stem Cell Therapy Key Players in North America (2019-2020)6.3 North America Cancer Stem Cell Therapy Market Size by Type (2015-2020)6.4 North America Cancer Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Cancer Stem Cell Therapy Market Size (2015-2020)7.2 Cancer Stem Cell Therapy Key Players in Europe (2019-2020)7.3 Europe Cancer Stem Cell Therapy Market Size by Type (2015-2020)7.4 Europe Cancer Stem Cell Therapy Market Size by Application (2015-2020) 8 China8.1 China Cancer Stem Cell Therapy Market Size (2015-2020)8.2 Cancer Stem Cell Therapy Key Players in China (2019-2020)8.3 China Cancer Stem Cell Therapy Market Size by Type (2015-2020)8.4 China Cancer Stem Cell Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Cancer Stem Cell Therapy Market Size (2015-2020)9.2 Cancer Stem Cell Therapy Key Players in Japan (2019-2020)9.3 Japan Cancer Stem Cell Therapy Market Size by Type (2015-2020)9.4 Japan Cancer Stem Cell Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Cancer Stem Cell Therapy Market Size (2015-2020)10.2 Cancer Stem Cell Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Cancer Stem Cell Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Cancer Stem Cell Therapy Market Size by Application (2015-2020) 11 India11.1 India Cancer Stem Cell Therapy Market Size (2015-2020)11.2 Cancer Stem Cell Therapy Key Players in India (2019-2020)11.3 India Cancer Stem Cell Therapy Market Size by Type (2015-2020)11.4 India Cancer Stem Cell Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Cancer Stem Cell Therapy Market Size (2015-2020)12.2 Cancer Stem Cell Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Cancer Stem Cell Therapy Market Size by Type (2015-2020)12.4 Central & South America Cancer Stem Cell Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 AVIVA BioSciences13.1.1 AVIVA BioSciences Company Details13.1.2 AVIVA BioSciences Business Overview13.1.3 AVIVA BioSciences Cancer Stem Cell Therapy Introduction13.1.4 AVIVA BioSciences Revenue in Cancer Stem Cell Therapy Business (2015-2020))13.1.5 AVIVA BioSciences Recent Development13.2 AdnaGen13.2.1 AdnaGen Company Details13.2.2 AdnaGen Business Overview13.2.3 AdnaGen Cancer Stem Cell Therapy Introduction13.2.4 AdnaGen Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.2.5 AdnaGen Recent Development13.3 Advanced Cell Diagnostics13.3.1 Advanced Cell Diagnostics Company Details13.3.2 Advanced Cell Diagnostics Business Overview13.3.3 Advanced Cell Diagnostics Cancer Stem Cell Therapy Introduction13.3.4 Advanced Cell Diagnostics Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.3.5 Advanced Cell Diagnostics Recent Development13.4 Silicon Biosystems13.4.1 Silicon Biosystems Company Details13.4.2 Silicon Biosystems Business Overview13.4.3 Silicon Biosystems Cancer Stem Cell Therapy Introduction13.4.4 Silicon Biosystems Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.4.5 Silicon Biosystems Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, the QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research teams with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

More here:
Cancer Stem Cell Therapy Market Size is Thriving worldwide with Topmost Companies Like: Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem...

Read More...

The COVID-19 Fallout: Cancer Stem Cells Market in 2020 What Does the Year Ahead Hold? – Crypto Daily

September 28th, 2020 4:54 pm

The COVID-19 tragedy is expected to create a positive impact on the global cancer stem cells market. The bladder cancer segment is projected to grab major share of the market. The targeted cancerous stem cells segment is projected to observe significant growth. The Asia Pacific region is expected to lead the global market throughout the forecast period. The major players of the market are implementing several strategies to withstand their business amidst this catastrophic situation.

At this moment in time, the whole world is in havoc owing to the abrupt outburst of COVID-19 pandemic. However, this pandemic situation has created a positive impact on the global cancer stem cells market. A latest report published by Research Dive reveals that the global cancer stem cells market is anticipated to gather $1,898.3 billion by 2026, rising at a growth rate of 11.8% from 2019 to 2026. The report segments the global market into application, cancer forms, and region. The report provides comprehensive analysis of the impact of COVID-19 on the key drivers, opportunities, limitations, key segments, and top players of the global market.

Regardless of the outbreak of COVID-19 pandemic, government bodies all over the world are hugely investing on research & development activities to enhance the use of cancer stem cells in the cancer treatments. Additionally, the development of stem cells for stem line banking and developing induced Pluri-Potent Stem Cell (PSC) lines is massively boosting the growth of the cancer stem cells market.

Based on cancer forms, the report categorizes the global cancer stem cells market into brain, breast, bladder, liver, blood, pancreatic, lung, colorectal, and other. The bladder segment is dominating the market ever since 2018 and is predicted to gather $303.9 million by 2026. This segment is expected to grow majorly owing to the rising number of deaths due to bladder cancer, all over the world. According to the U.S. government, bladder cancer is the fifth most occurring cancer among all other types of cancer, and therefore it is optimistically influencing the global market growth throughout the projected period.

Based on application, the report divides the global market into targeted cancerous stem cells and stem cells-cancer therapy. Among these, the targeted cancerous stem cells segment is anticipated to observe significant growth at a CAGR of 13.0% throughout the projected period. As targeted cancerous stem cells have the ability to attract normal cells, they can be used positively to target cancer cells; this factor is greatly boosting the growth of this segment.

Regionally, the report studies the market across North America, Asia-Pacific, Europe, and LAMEA. Among these, the Asia-Pacific region is anticipated to lead the global market by garnering $405.17 million by 2026. This is mostly due to the presence of considerable number of scientists in this region that are involved in R&D activities related to stem cell therapy.

The prominent players in the global cancer stem cells market areMerck KGaA, AbbVie Inc., Irvine Scientific, Stem Cell Technologies Inc., MiltenyiBiotec, Thermo Fisher Scientific Inc., OncoMed Pharmaceuticals, Sino Biological Inc., BioTime Inc., and others.These market players are implementing various tactics to survive during this pandemic situation.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Continued here:
The COVID-19 Fallout: Cancer Stem Cells Market in 2020 What Does the Year Ahead Hold? - Crypto Daily

Read More...

North America to Continue with its leading Streak in the Animal Stem Cell Therapy Market – Crypto Daily

September 28th, 2020 4:54 pm

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involve three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.

Animal Stem Cell Therapy Market: Drivers and Restraints

Increasing prevalence of disease in animals with growing population and to increase the animals quality of life, the companies focus shifting towards animal stem cell therapies. Along with increasing government funding for the protection of animals and fast approvals of FDA contributing towards the rapid growth of the animal stem cell therapy. The research in animal stem cells offers great promise for understanding underlying mechanisms of animal development; it gives great opportunities to treat a broad range of diseases and conditions in animals. Animal stem cell therapy is increasingly recognized as critical translational models of human disease for treatment. All these factors act as drivers for the robust growth of the animal stem cell therapy market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/14941

Animal Stem Cell Therapy Market: Segmentation

Segmentation based on Applications

Segmentation based on End-user

Animal Stem Cell Therapy Market: Market Overview

Studies in the animal stem cell therapy continue at a breathtaking pace due to increasing demand and treatment cost covered in reimbursements. And animal stem cell therapy is more effective than traditional treatment available in the market which is boosting the companies to increase the spending in the R&D for innovative methods. Because of the novelty and complexity of animal stem cell therapy, FDA encourages individuals, universities and drug companies for further innovations. The future expected with double CAGR during the forecasted period.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/14941

Animal Stem Cell Therapy Market: Region-wise Overview

Regarding geographies, North America is dominating the global animal stem cell therapy market due to the increased incidence rate and awareness about the therapy. U.S represents the largest market share in the North America due to the increasing demand for the therapy. Europe and Asia-Pacific are showing a significant growth rate during the forecasted period due to the growing adoption of the animal stem cell therapy. The animal stem cell therapy market in underdeveloped countries is slow when compared to the developed countries.

Animal Stem Cell Therapy Market: Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/14941

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
North America to Continue with its leading Streak in the Animal Stem Cell Therapy Market - Crypto Daily

Read More...

Health and Human Performance prof Lois Jackson honoured by Canadian Academy of Health Sciences – Dal News

September 26th, 2020 6:00 am

One of Dalhousies own has become a Canadian Academy of Health Sciences (CAHS) Fellow, one of the highest honours for members of the countrys health sciences community.

Lois Jackson, a professor in Dals School of Health and Human Performance, is internationally recognized for her community-based, collaborative research with marginalized populations. Her highly productive program of research identifies how social inequalities impact access to health services, and her work draws attention to inequities across urban and rural places. She is a leader in population health research, providing a voice for communities living socially and economically on the margins of society.

It is a true honour to be elected into the Canadian Academy of Health Sciences (CAHS) as a 2020 Fellow, says Dr. Jackson. The Academy is a unique organization providing assessments and advice on various critical issues that are important to the health of the Canadian population.

I am absolutely thrilled that I will be able to contribute to the Academys work, and I very much look forward to engaging with the many Fellows whose expertise on key health issues crosses a diverse range of disciplines in the health sciences.

The Canadian Academy of Health Sciences brings together Canadas top-ranked health and biomedical scientists and scholars to make a positive impact on the urgent health concerns of Canadians. CAHS Fellows are chosen through a peer review process for their demonstrated leadership, creativity, distinctive competencies, and commitment to advancing academic health sciences. They agree to serve the Academy and be active in promoting improved health, health care and health-related policies. Dr. Jackson joins a cohort of 77 new Fellows this year.

Congratulations to Dr. Jackson on this well-deserved recognition from the Canadian Academy of Health Sciences, says Alice Aiken, vice-president research and innovation at Dalhousie. She embodies the true meaning of a research scholar, displaying great rigor, integrity and humility as she works to support those who are seeking equal access to health care and social support from coast to coast to coast in Canada.

Born and raised in Toronto, Dr. Jackson completed her BA, MA and PhD (Sociology) at the University of Toronto, where she also completed a post-doctoral fellowship (Department of Preventative Medicine and Biostatistics) focused on HIV prevention research. Following her post-doctoral fellowship, she worked in the City of Toronto Department of Public Health as a research program consultant, after which she began a tenure-track position at Dalhousie.

It was when I was a post-doctoral fellow that I became involved in community-based research working with a small non-governmental organization providing HIV prevention education for women involved in the sex industry, says Dr. Jackson. This research, and my work with the City of Toronto Department of Public Health, made me realize how important social conditions are to shaping a populations health.

She was able to bring her academic training to her community-based health research. That began a career of working with different community-based organizations and people with lived experience, to examine and highlight how various structural forces such as poverty and stigma negatively impact the health of diverse populations.

Throughout her career, Dr. Jackson has been the recipient of many awards and accolades. In 2000, she received a Canadian Institutes of Health Research (CIHR) Investigator/Regional Partnership Award for her work on the social determinants of health and studies involving marginalized populations, which marked significant national recognition of the importance of her research. She also received the 2017 Public Health Champion Award from the Public Health Association of Nova Scotia, and more recently Health Promotion Canadas 2018 Team Award (with Mainline Needle Exchange and Direction 180), in recognition of her community-based research in improving the health of those living on the margins.

In addition, Dr. Jackson was acknowledged by her colleagues in 2015 with the Patricia Cleave Outstanding Leadership Award for the Faculty of Health. This award was presented in recognition of her leadership in the transformation of the forward-thinking, rebranded,re-conceptualized Healthy Populations Institute (HPI). And, in August 2020, she was named as Dalhousies newest University Research Professor.

To learn more about the Canadian Academy of Health Sciences, visit the CAHS website.

Read more from the original source:
Health and Human Performance prof Lois Jackson honoured by Canadian Academy of Health Sciences - Dal News

Read More...

Common conditions that can contribute to COVID-19 deaths – Twin Falls Times-News

September 26th, 2020 6:00 am

The coronavirus death toll in the United States surpassed 200,000 on Sept. 22, which the Associated Press equated to a "9/11 attack every day for 67 days."

Many of these deaths have involved COVID-19 and at least one other condition, which is called a comorbidity. In some cases, coronavirus directly causes comorbid conditions like pneumonia or sepsis. Other comorbid conditions such as diabetes and hypertension are preexisting, but may complicate a patients reaction to COVID-19 and cause them to suffer a more serious outcome. The Centers for Disease Control has found that in as many as 94% of COVID-19-caused deaths, individuals also had a contributing comorbidity.

Stacker analyzed a National Center for Health Statistics dataset on conditions contributing to deaths involving coronavirus disease to examine common conditions that may contribute to COVID-19 deaths. The deaths tabulated in this dataset include Americans who had confirmed cases of COVID-19 and one or more other diseases or health conditions at the time of death. This story includes the deaths associated with COVID-19 and 21 common conditions from Feb. 1 to Aug. 15, 2020.

Keep reading to find out which common conditions can most contribute to COVID-19 fatalities.

You may also like: COVID-19 is the latest example of zoonosishere are 30 other diseases animals transmit to humans

Link:
Common conditions that can contribute to COVID-19 deaths - Twin Falls Times-News

Read More...

Prevention Efforts Prove Critical With Heightened Risk Of Legionella In School Water Systems – PRNewswire

September 26th, 2020 6:00 am

GALESBURG, Ill., Sept. 23, 2020 /PRNewswire/ --The COVID-19 pandemic forced K-12 schools to not only close their doors suddenly and unexpectedly, but to keep them closed for an unusually long period of time. Due to the prolonged shutdown, stagnant water left sitting in the pipes and plumbing systems of school buildings now poses a great threat of Legionella bacteria growth which can cause Legionnaires' disease, a type of severe pneumonia that can lead to death. Though there is always a risk of Legionella in stagnant water systems, schools may be at a much higher risk now due to the several months-long closures and continued low-occupancy which may allow for higher concentrations of Legionella to develop.

As schools across the country work to reopen, Intellihot, a leading commercial tankless water heating manufacturer, implores K-12 school administrators to take preventative health and safety measures such as proactively flushing all piping and water-using devices and to consider long-term solutions like tankless hot water heaters in order to minimize the risk of Legionnaires' disease and other waterborne hazards and diseases.

In just the past 30 days, Legionella has already been found in at least 10 schools in multiple towns in Ohio and Pennsylvania and experts predict there will be more. A report from the National Academies of Sciences, Engineering, and Medicine titled Management of Legionella in Water Systems, estimates that about 52,000 to 70,000 Americans suffer from Legionnaires' disease each year. According to Centers for Disease Control and Prevention (C.D.C.), in the United States, the rate of reported cases of Legionnaires' disease has grown by nearly nine times since 2000. Dr. Andrew Whelton, an associate professor of civil, engineering and environmental and ecological engineering at Purdue University, has studied the implications of water stagnation in school plumbing systems and has been vocal about the action school administrators and public health officials should take to reduce the risk for widespread disease before students, teachers and staff return to school.

"Widespread building shutdowns brought on by COVID-19 are unprecedented. Buildings aren't designed for these shutdowns, and water needs to stay moving to prevent bacteria and metal from concentrating in the pipes. Students and staff could be at risk of serious health issues if pipes aren't properly flushed before they return," said Whelton. "Even when schools reopen, fewer people in the buildings means lower water use. Problems need to be avoided with operating buildings at low occupancy, too."

The most common form of Legionella transmission occurs by breathing in contaminated water droplets or mist from sources such as drinking fountains, sinks and showers. Legionnaires' disease cannot be spread from human-to-human contact and the majority of cases can be successfully cured with antibiotics. However, because Legionnaires' disease shows similar respiratory signs and symptoms as COVID-19, there are additional concerns that those with Legionnaires' disease may be misdiagnosed with COVID-19 and thus, left untreated.

The traditional water heating systems used by many schools today are outdated, unreliable and require huge storage tanks that can grow and amplify Legionella and other microbial hazards such as leaching metals. Water safety must be examined before schools reopen and tankless water heating systems should be evaluated as a long-term solution to mitigate the risk of Legionella.

Designed for schools, hotels and other large facilities, Intellihot's groundbreaking commercial tankless water heaters are able to heat unlimited amounts of water on demand without the need to store any water which significantly reduces the risk of Legionella. The compact, floor-mounted units are drop-in-ready, fit existing water and gas connections, eliminate the need to re-pipe, and require very little installation time. Intellihot tankless systems also eliminate waste and environmental impact, and cut down greenhouse emissions by over 40%.

Intellihot commercial tankless water heaters power K-12 schools, educational institutions and Ivy-league universities around the country.

"Legionnaires' disease is very preventable. With a few simple steps and inexpensive precautions, school administrators can reduce the risk," said Sri Deivasigamani, co-founder and CEO of Intellihot. "If you haven't already considered a tankless water heating system as part of your school's water management plan, now is the time to do so. In addition to health and safety benefits, Intellihot tankless units save money, improve your school's carbon footprint and can be quickly installed before occupants return."

Though there are currently no government or industry standards for schools to safely reopen and to return plumbing to normal use following the extended closures, the C.D.C. has published voluntary guidelinesto aid building owners and property managers aiming to prevent Legionella from spreading as facilities reopen.

About Intellihot, Inc.Founded in 2009 in Peoria, Illinois, Intellihot is a clean technology, IoT company with a mission to do more with less and to create intelligent energy transformations. Today, Intellihot builds IoT devices and commercial tankless water heaters that help their customers cut energy costs and eliminate downtime. With customers like Abigail Adams Middle School, Levi's Stadium, home of the San Francisco 49ers, 340 on the Park, Chicago's second tallest residential building, Costco and Marriott International, Intellihot is working towards a waste-free future in schools, homes, businesses and facilities across the planet. Learn more atwww.intellihot.com.

SOURCE Intellihot

Read the original post:
Prevention Efforts Prove Critical With Heightened Risk Of Legionella In School Water Systems - PRNewswire

Read More...

Bonitas medical aid announces price increases and 2 new plans for 2021 – BusinessTech

September 26th, 2020 6:00 am

South Africas second largest open medical aid scheme, Bonitas, has announced a weighted increase of 4.6% across all its plans for 2021 ranging between 0% and 7.1%.

The 0% increase is for the BonFit Select plan, the group said, adding that members on its growth options making up 91% of business will only experience an increase of 3.9%.

The guidelines received from the Council for Medical Schemes (CMS), clearly highlighted that medical schemes should limit contribution increases as far as possible. We crunched numbers and worked tirelessly to find the sweet-spot between sustainability and ensuring affordability, said Lee Callakoppen, principal officer of Bonitas Medical Fund.

Bonitas noted that seven of its current options are priced between R1,500 and R3,000 per month, which is where the medical scheme market is experiencing growth currently.

Member behaviour has changed significantly and demand is for innovation, accessibility and technology. This has the benefit of attracting, a younger, target audience and driving sustainability, it said.

The group has introduced two new plans for 2021, which enter a technology-driven category called Edge.

The plans: BonStart and BonStart Plus, are designed for economically active singles or couples, living in the larger metros.

The plans include access to:

The cost for the plans are R1,452 and R1,731 respectively for the principal member.

Due to the Covid-19 pandemic, and the changing trends both globally and locally, Bonitas said it will focus more on core services like managed care for growing health risks (diabetes, high blood pressure, oncology) as well as the drive for home-based care.

It is also promoting the use of day hospitals and clinics, where possible, for procedures which are better suited to such facilities.

Other focus areas for 2021 include:

Our focus is on more primary healthcare, utilisation of preventative care benefits, digitally enabled solutions and self-help facilities for members who want access to their benefits 24/7, the group said.

Our goal is to improve integration of care, enable more access to out-of-hospital services, clinical information and benefits via various solutions.

Read: Momentum Medical Scheme reveals annual increase for 2021

More here:
Bonitas medical aid announces price increases and 2 new plans for 2021 - BusinessTech

Read More...

Royal Caribbean and Norwegian Reveal the Healthy return of Sailing – Cruise Industry News

September 26th, 2020 6:00 am

New recommendations from a panel of medical and scientific experts say that by relentlessly focusing on prevention and other measures, including the testing of guests and crew, public health risks associated with the pandemic can be mitigated in a cruise ship environment, according to a joint project from Royal Caribbean Cruises and Norwegian Cruise Line Holdings.

The Healthy Sail Panel submitted its recommendations today to the U.S. Centers for Disease Control and Prevention (CDC), in response to a CDC request for public comment that will be used to inform future public health guidance and preventative measures relating to travel on cruise ships.

The Healthy Sail Panel's 65-plus-page report includes 74 detailed best practices to protect the public health and safety of guests, crew and the communities where cruise ships call, according to a statement.

Recommendations include testing, the use of face coverings, and enhanced sanitation procedures on ships and in terminals.

The Panel is chaired by Governor Mike Leavitt, former U.S. Secretary of Health and Human Services, and Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration.

"The Healthy Sail Panel spent the last four months studying how to better protect the health and safety of guests and crew aboard cruise ships," said Dr. Gottlieb. "Taken as a comprehensive approach, we believe the Panel's robust public health recommendations will help inform strategies for a safe resumption of sailing."

Gov. Leavitt said: "This Panel undertook an ambitious, cross-disciplinary, public health examination to develop standards and guidelines that create the highest level of safety in the complex environment of a cruise ship. We studied the industry's experiences combating the pandemic and we then incorporated the many lessons learned and advances made by medicine and science over the past six months. The Panel's recommendations are grounded in the best scientific and medical information available and are intended to meaningfully mitigate public health risks to those who sail."

"We understand our responsibility to act aggressively to protect the health and safety of our guests and crew, as well as the communities where we sail, and we asked the Panel to help us learn how to best live up to that responsibility," said Richard D. Fain, chairman and CEO of Royal Caribbean Group. "We were inspired by the depth of the Panel's work and their determination to help us establish the strongest protocols in the travel industry."

"The Healthy Sail Panel's recommendations are robust and comprehensive, and they reflect the intense focus the panelists brought to their work," said Frank Del Rio, president and CEO of Norwegian Cruise Line Holdings Ltd. "We know that both authorities around the globe and consumers expect cruise lines to provide the safest, healthiest vacations we can, and this work demonstrates our commitment to doing just that."

Fain and Del Rio said each company will use the Panel's recommendations to inform the development of new, detailed operating protocols, which will be submitted to the CDC and other authorities around the globe for review and approval.

The Panel's work is open sourced for others to incorporate in their protocols as well; Governor Leavitt and Dr. Gottlieb expressed appreciation that authorities and other cruise companies had already engaged in the Panel's work as observers.

The Healthy Sail Panel identified five areas of focus every cruise operator should address to improve health and safety for guests and crew, and reduce the risk of infection and spread of COVID-19 on cruise ships:1. Testing, Screening and Exposure Reduction 2. Sanitation and Ventilation 3. Response, Contingency Planning and Execution 4. Destination and Excursion Planning 5. Mitigating Risks for Crew Members

In each category, the Healthy Sail Panel created practical and actionable recommendations to address specific safety concerns. Among the recommendations are key strategies such as: Taking aggressive measures to prevent SARS-CoV-2 from entering a ship through robust education, screening and testing of both crew and guests prior to embarkation Reducing transmission via air management strategies and enhanced sanitation practices Implementing detailed plans to address positive infection on board, including contingencies for onboard treatment, isolation and rapid evacuation and repatriation Closely controlling shore excursions Enhanced protection for crew members

Read this article:
Royal Caribbean and Norwegian Reveal the Healthy return of Sailing - Cruise Industry News

Read More...

Asbestos Awareness and Education – Mesothelioma.net Blog

September 26th, 2020 6:00 am

This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.

We make every attempt to keep our information accurate and up-to-date.

Please Contact Us with any questions or comments.

Asbestos use is in decline, but exposure to this harmful material is still possible, especially in occupational settings. Many victims of exposure have developed mesothelioma, but experts in abatement, prevention, medicine, and advocacy are helping these people and preventing future exposure.

Asbestos is a group of minerals made of silicon and oxygen and with a fibrous structure. People have mined and used asbestos for hundreds of years because of its unique properties:

Asbestos use in the U.S. took off in the late 1800s, but peak asbestos use occurred from the 1930s through the 1970s. Many industries used asbestos in materials, mostly for fireproofing and insulating. Some of the most significant users of asbestos historically were companies that made construction materials and components for ships.

Asbestos did not come under scrutiny until a connection was finally made between exposure to the fibers and poor respiratory health. The first regulations on asbestos use came in the 1970s.

The Environmental Protection Agency banned asbestos completely in 1989, but the Fifth Circuit Court of Appeals overturned it. Today, asbestos use is limited. It still lingers in older materials.

Mesothelioma is a cancer of the mesothelium, the tissue lining organs in the body. Asbestos is the leading cause and risk factor, although the link has not always been understood. Mesothelioma can occur around the lungs, in the abdomen, around the heart, or very rarely in the testicles.

Pleural mesothelioma, around the lungs, is the most common type. This is because asbestos exposure typically occurs through inhalation of the fibers. Peritoneal, the abdominal type, is the second most common.

Mesothelioma is aggressive, spreads rapidly, is difficult to treat, and is almost always terminal. Survival rates are relatively low for this cancer.

Doctors first described pleural and peritoneal tumors in the 1700s and 1800s, respectively. A pathologist first used the word mesothelioma in 1920.

The earliest connection experts made to asbestos was in the 1930s. Doctors found that people with asbestosis, scarring in the lungs caused by asbestos fibers, also often had tumors.

In 1960, researchers in South Africa published a paper that linked cancer with mined asbestos. They noted that mesothelioma occurred much more often in the part of the country with asbestos mines.

In 1964, a doctor in the U.S. reported that asbestos insulation workers had high mortality rates from asbestosis and cancer. After these studies, evidence that asbestos causes mesothelioma continued to grow.

Occupational exposure is the main source of asbestos exposure. Secondary exposure from workers who bring fibers home on their clothing and exposure through nearby industries or naturally-occurring asbestos is much less common.

Historically, some of the industries that carried the highest risks of asbestos exposure for workers included:

Today, these jobs are safe, thanks to asbestos regulations. However, asbestos is still used in some materials and lingers in many materials these workers encounter.

All construction workers still face asbestos risks, but especially those in demolition and who repair or renovate older buildings. The same is true of older ships and auto mechanics working with asbestos parts in older cars.

A military career can also cause asbestos exposure, although that risk is much lower today. Nearly one-third of all mesothelioma diagnoses are in veterans. Navy veterans have the highest rates because of the extensive use of asbestos on ships.

The U.S. Veterans Administration offers compensation and healthcare to veterans whose asbestos exposure occurred during service. In addition to world-class care at leading VA hospitals, veterans may also be eligible for disability compensation.

Diagnosing mesothelioma is difficult. The symptoms of pleural and peritoneal mesothelioma are typically mild until the cancer is advanced:

Many victims of asbestos exposure are misdiagnosed because these symptoms are similar to more common illnesses. Often the true diagnosis comes later, when the cancer is advanced and more difficult to treat.

Diagnosis for mesothelioma typically includes a physical exam; an X-ray to rule out other illnesses; more advanced imaging scans to look for tumors; a biopsy to determine if cells are malignant and part of the mesothelium; and blood tests to look for mesothelioma-specific markers.

Treatment for mesothelioma depends on the type, the cell structure, the stage, and the patients health and preferences. Most patients receive some combination of:

Mesothelioma is challenging to treat for several reasons: It is often diagnosed in later stages; the tumors are multiple and small, making surgery a challenge; and the cancer is aggressive and spreads rapidly. Too often, the standard treatments are inadequate to extend life by more than months or a year.

Researchers keep working on newer, better treatments to help patients live longer. Some important advances include:

Asbestos abatement, the safe removal of asbestos materials, is often needed in older buildings constructed during heavy asbestos use. Abatement professionals must be trained to do this skilled work and licensed by the state in which they work.

Homeowners may use home test kits to determine if they have asbestos or call in professionals to do it. Once the presence of asbestos is known, abatement usually follows these steps:

Most asbestos is disposed of, but technological advances may make it possible to recycle materials contaminated with the mineral.

Because asbestos lingers in so many older buildings, abatement professionals will continue to find work. Becoming an abatement professional does not require a degree. Most workers receive on-the-job training and then earn licensing through the appropriate state department. Workers may also become abatement managers with experience and additional training.

According to the U.S. Bureau of Labor Statistics, careers for skilled hazardous materials removal workers are growing. Abatement is not limited to asbestos. These workers also handle and remove lead, mold, radioactive materials, and harmful chemicals. Job responsibilities include:

Construction companies, asbestos, and other hazardous materials abatement contractors, government agencies, environmental companies and organizations, and disaster response organizations employ hazmat removal workers.

Abatement professionals play an important role in preventing asbestos exposure. Other professionals work with the victims of exposure who have become ill:

Victims of asbestos exposure and mesothelioma, and their loved ones, can benefit from charities, support groups, awareness events, and other resources:

The Meso Foundation began Mesothelioma Awareness Day, which takes place every September 26. The organization hosts nationwide events, and local groups create smaller events to raise awareness for this rare cancer.

The coronavirus pandemic has made life difficult for everyone, but patients with compromising illnesses like mesothelioma are most affected. Patients have felt the impact in a few ways:

Mesothelioma is a terrible diagnosis, and so many cases could have been prevented. Today, professionals who work in abatement, medicine, and non-profit organizations are helping victims and ensuring no one has to suffer from asbestos exposure anymore.

Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.

Sources

Follow this link:
Asbestos Awareness and Education - Mesothelioma.net Blog

Read More...

Combine Cardio and Strength With This 20-Minute Jump Rope and Dumbbell Workout – LIVESTRONG.COM

September 26th, 2020 5:59 am

Jump rope is an easy, minimal-equipment way to get your heart rate up.

Image Credit: Innocenti/Cultura/GettyImages

Combining strength training and cardio in the same workout is a fantastic way to multitask. From increasing endurance to blasting calories to building lean muscle to gaining strength, consider the two a perfect pair.

Strength training builds muscle, which can help boost your metabolism and burn more calories at rest, according to the Mayo Clinic. Cardio, on the other hand, is amazing for supporting heart health, burning calories and increasing the "feel good hormones," such as serotonin, according to a April 2019 study published in Preventative Medicine.

So grab your jump rope and a set of dumbbells and get ready for a heart-pumping, strength building, fat-blasting workout!

Do: each of the exercises below, alternating between jumping rope for 30 to 60 seconds and performing 15 reps of the dumbbell exercise listed. Rest for 30 to 60 seconds before repeating the circuit once more.

The curling motion can be performed three ways: alternating arms, both arms at the same time or one arm at a time.

Don't let your knees go forwards past your toes.

Visit link:
Combine Cardio and Strength With This 20-Minute Jump Rope and Dumbbell Workout - LIVESTRONG.COM

Read More...

Dr. Birx praised Texas A&Ms low COVID rates. Its higher than both Rice and Baylor. – Houston Chronicle

September 26th, 2020 5:59 am

White House Coronavirus Response Coordinator Dr. Deborah Birx visited Texas A&M Universitys campus Tuesday and praised its COVID-19 positivity rate, saying its one of the lowest shes seen, but is it really low?

The College Station flagship, which has more than 65,000 students and 10,160 faculty, reported that its weekly positivity rate for its random testing program, which includes student test results collected at special testing sites in the area, was 1.6 percent for the week ending on Sept. 12, according to A&Ms online dashboard. Tests in this program are performed specifically by its Student Health Services in efforts to identify students who are asymptomatic or where there are hotspots for transmission.

Texas A&Ms overall positivity rate, however which includes results of students, faculty and staff was around 10 percent. The college reports that tests factored into this postivity rate are conducted by both its health services and contracted company Curative Inc. within the Bryan-College Station area. The university also reported that more than 600 students and 23 faculty have tested positive this month, and 255 of these cases are still considered active as of Sept. 22.

A White House media representative did not immediately respond to requests for comment.

Ten percent seems pretty high to me, said Peter Hotez, co-director of Texas Childrens Hospitals Center for Vaccine Development. Maybe she was looking at the wrong number.

Compared to other Texas colleges, like Rice and Baylor universities, both of which provide their positivity rates and cases online and test both asymptomatic and symptomatic individuals like Texas A&M, Texas A&M results are higher.

Birx also visited Auburn University, Louisiana State University, and Virginia Tech University. University of Kentucky, USC, Columbia

Rice, with about 8,000 students, reported a 0.09 percent positivity rate on its dashboard as of Thursday morning. The private Houston college has had 21 people test positive for the virus since Aug. 1 13 of them students and eight of them faculty or staff.

On HoustonChronicle.com: White House official Birx praises A&Ms low COVID-19 rates, vaccine manufacturing

Kevin Kirby, Rice vice president for administration, said positivity rates between different schools can vary depending on the testing strategy. For example, some schools test only those who are symptomatic, which can result in higher positivity rates. At Rice, officials test both those with and without symptoms, which can result in a lower positivity rate.

But Kirby adds that Rice has some structural advantages compared to many larger universities.

For one, Rice is situated next to the Texas Medical Center, which has been a crucial resource when it comes to testing and advice, Kirby said. Additionally, the opportunity and temptation of being around more people or to attend events, which can spread a virus, can be stronger at larger institutions. Rice also doesnt have fraternities and sororities, which Kirby believes has helped.

Rice has also aimed to implement best practices used at colleges around the country, including wearing masks, limiting class sizes, testing and prompt delivery of results. In addition, the college gives students and faculty the option of how they would like to engage in instruction and education, whether it be in-person, remote or hybrid.

Birx also visited Baylor University Monday. The Waco college boasts a 2.6 positivity rate as of Thursday, with 75 active COVID-19 cases reported within its community on Sept. 24 a drastic decline from the 477 cases reported on Sept. 3. Nearly all of its current active cases are students.

Baylor spokesman Jason Cook credits the private Baptist colleges decline to following the Centers for Disease Control and Preventions guidelines on contract tracing, maintain social distancing, and adamant enforcement of masks and face coverings.

Cook said many colleges went into the semester expecting that there would be a spike in cases at some point.

Our students have indicated they want to be on campus for the fall semester and that has been a great motivating factor, Cook said. That desire from students prompted Baylor officials to prepare the college on how it would manage a spike with preventative education, quarantine efforts, and mask wearing.

As a result, Cook said Baylor, which enrolled 19,297 students this fall, has not had any COVID-19 cases linked to classrooms.

A lot of it is the infrastructure of the institution leading into the semester coupled with the ability to institute behavior change, Cook said.

As for Birxs assessment of low COVID-10 positivity rates, Hotez questions whether it is a reliable statement.

The White House Coronavirus Taskforce is such an unreliable source of information, Hotez said. Theres often a heavy political spin on it. Its really hard to sort out whats right, and its getting worse now.

Hotez, who also serves as dean of the National School of Tropical Medicine at Baylor College of Medicine, has predicted that there will be a third peak or surge of the virus later this fall, following the first in April-May and the second peak in Southern states in July-August. The third peak, he said, could be the worst, contributed to colleges and schools reopening for on-campus learning.

Hotez said in some cases U.S. colleges and universities have opened in areas of high transmission and are a bit oblivious to the greater impact on the communities and states that theyre in.

In-person voting in November, considering the restrictions to mail-in voting, could also contribute to an uptick, Hotez said.

Without more awareness and strong leadership, especially in the Southern states, its not going to go well, he said.

brittany.britto@chron.com

Read more:
Dr. Birx praised Texas A&Ms low COVID rates. Its higher than both Rice and Baylor. - Houston Chronicle

Read More...

From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma – OncLive

September 26th, 2020 5:59 am

Ophthalmologists are filling a critical role in the collaborative management of patients with relapsed/refractory multiple myeloma who are receiving belantamab mafodotin-blmf (Blenrep), said Shaily Shah, MD, who added that the potential ocular toxicities that can occur with the antibody-drug conjugate (ADC) require consistent screening and management.

As a junior attending, what opened my eyes has been how incredible the field of medicine is in general, and how eager people are to work together to do what is best for the patient, Shah said. It is very exciting, in general, [that] oncology is a multidisciplinary specialty.

On August 5, 2020, the FDA approved belantamab mafodotin for use in patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 agent.1

Findings from the DREAMM-2 trial, which served as the basis for the approval, demonstrated a 31% overall response rate (ORR) with the recommended 2.5 mg/kg dose of belantamab mafodotin (n = 97).2 The ORR was 34% among patients who received the 3.4-mg/kg dose (n = 99).

Grade 3/4 keratopathy was observed in 27% of patients who received the 2.5 mg/kg dose versus 21% of patients who received the 3.4 mg/kg dose.

At 13 months of follow-up, deep responses were seen; more than half of responders in the 2.5 mg/kg (58%) and 3.4 mg/kg groups (66%) achieved a very good partial response or better.3

No new safety signals were identified with longer-term follow-up. Although keratopathy was common, only 6 patients discontinued treatment due to corneal events, suggesting that they were well managed with dose modifications.

According to Shah, with this ocular safety signal, patients treated with belantamab mafodotin should receive prophylactic treatment for dry eye, as well as have routine eye examinations to ensure ocular changes are identified early.

There is still a lot to be learned here, said Shah. Of course, the studies have been done, but now that belantamab mafodotin is going to be prescribed on a larger scale, there is going to be so much that we learn specifically regarding that agent, as well as how we can improve collaborative management for these patients.

In an interview with OncLive, Shah, an assistant attending ophthalmologist at NewYork-Presbyterian Hospital and an assistant professor of ophthalmology at Weill Cornell Medicine, discussed disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

OncLive: What is the frequency of disease-related ocular toxicities among patients with cancer?

Shah: I dont have an exact percentage offhand, but [ocular toxicities] are more common than one may think. Oftentimes, it is not related to the cancer itself but, there are certain types of cancers that manifest with ocular findings, such as some lymphomas and leukemias. Multiple myeloma in itself can produce crystalline keratopathy, but it is uncommon that we see that.

How frequently are treatment-related ocular toxicities observed in oncology?

Treatment-related adverse effects (TRAEs) are fairly common to see. At Cornell, we are right next to Memorial Sloan Kettering Cancer Center, so we see quite a few patients with graft-versus-host disease (GVHD), as well as patients who have received bone marrow transplants for leukemia. Those patients will often develop significant ocular toxicity from their systemic GVHD. Patients will sometimes come in with severe dry eye, lack of tear production, corneal haze, or corneal opacities. Patients could eventually develop limbal stem cell deficiency and go down a path of significantly decreased quality of life and visual acuity.

We have gotten good at having a protocol in place for our patients with GVHD. We know that patients may not respond to typical dry eye management, so we have steps to help them.

There are also certain medications such as chemotherapeutic agents that can cause cancer treatment-related ocular toxicities. We know that treating breast cancer with tamoxifen can cause retinopathychanges in the retina of the eye where crystal-type deposits [form] in the macula.

We may also see radiation-related toxicities in patients who had radiation near the face or around the chest and neck. Oftentimes, these patients will have problems with their tear ducts, tear drainage system, and sometimes, their tear production glands. They may develop significant dry eye either from scarring of the eyelids where they cant blink easily and the eyes dry out from exposure, or from a problem with tear production or drainage.

What ocular toxicities have been observed with belantamab mafodotin specifically? What sort of issues could arise if these AEs are not managed correctly?

Certainly, now with [the approval of] belantamab mafodotin, we have been seeing corneal toxicities [in patients with myeloma]. Throughout the clinical [trial] process for belantamab mafodotin with the DREAMM-1 and DREAMM-2 studies, the ocular toxicities [observed were] specific to the ocular surface. When [investigators] studied that further, they found that it [has] a corneal epithelial pathology. The cornea is the most superficial layer of the eye, and the epithelium is the most superficial layer of the cornea. Therefore, it is really [on] the most superficial layer of the ocular surface that we are seeing the majority of these toxicities.

Even just being confined to 1 portion of the tissue, the range of symptoms that the patient can feel is broad. Patients could be completely asymptomatic [although] the [ocular] changes are seen on the exam from the physicians standpoint, or the exam may not show changes, but the patient could have significant ocular surface-related complaints.

In general, these complaints will be similar to dry eyerelated complaints, including burning, grittiness, a foreign body or sandy sensation, an achy sensation, redness, and significant tearing. Oftentimes, patients may experience decreased visual acuity, so they may come in with complaints of blurred vision.

Our exam findings can range from no findings at all, to mild or moderate dry eye. We would see signs of dryness on the surface exam where a dye used to stain the surface of the cornea can pick up changes that correlate with dry eye and highlight dry spots in the corneal epithelium.

In terms of parameters, we look at whether there are any staining patterns. Are there any punctate epithelial erosions? An interesting finding that we have seen, and that was reported after the DREAMM-1 and DREAMM-2 studies, is microcystic keratopathy. These are small microcysts that we can see just underneath the surface layer of the epithelium.

[Microcysts] usually start in the periphery of the cornea and work their way in toward the center. That is consistent with what the studies had shown. Initially, the 2 patients I had seen who developed microcysts were completely asymptomatic. They came in for a routine follow-up with no visual complaints and their vision hadnt changed on their exams. It was an incidental finding.

Corneal exams [can also show] corneal haze. Again, this very fine opacity starts around the edges of the cornea and can eventually progress to the center. Sometimes the exam findings are correlated with patient symptoms such as blurred vision or discomfort, but again, patients may be completely asymptomatic.

It is important to screen these patients. If they do not have symptoms, they wont necessarily come in of their own accord. We have a great system in place where right before every infusion, we see patients for screening exams.

If a patient on belantamab mafodotin does develop ocular toxicities, what are some of the management strategies that can be used to treat these AEs?

With this expanded access [program] that I have been part of at Cornell through GlaxoSmithKline, the protocol that we have in place is to treat our patients prophylactically with artificial tears. We will start patients on preservative-free artificial tears anywhere from 4 to 6 times a day, or more if patients get [relief] from them. The idea is to lubricate the eyes and keep them as healthy and wet as possible to try to minimize discomfort and surface level toxicity.

One of the proposed pathophysiologic mechanisms for why corneal toxicity occurs is that some of the drug may be carried in through the tear film of the patient. Then every time that patient blinks and produces tears, the drug sits on the surface of their eye. In addition to keeping patients comfortable and preventing dry eye symptoms, artificial treats help to dilute their natural tear film and potentially prevent toxicity from building up.

Even if patients dont have dry eye, but they have any other eye conditions that can contribute to dry eye such as meibomian gland dysfunction (MGD), I will oftentimes have them start treatment for that ahead of time. The treatment [for MGD] is simple. At home, patients are asked to use warm compresses to try to open up the glands to increase oil production and improve the quality of their natural tears.

At this point, most treatment is preventative, and we try to maximize patients ocular health before they even start treatment. As soon as I see them for screening, I will go over the details of what the [potential] toxicities are and why it is so important to start these preventative treatments.

Additionally, some studies have shown that putting a cold compress on the eye during the time of infusion can increase patients comfort levels and potentially improve the ocular toxicity profile. That is also something that is built into our protocol.

How do these ocular toxicities affect the use of belantamab mafodotin?

It depends on the level of toxicity the patient is experiencing. If patients have mild toxicity with a little bit of dry eye on the exam, no significant haze, no microcysts, and they are asymptomatic, we would call that grade 1 toxicity. Patients can usually continue with their treatment as planned.

If they start to develop peripheral microcystic changes or corneal haze, with or without changes in their visual acuity, oftentimes we will dose reduce or halt the next dose of belantamab mafodotin until they resolve back to grade 1 or baseline.

If a patient has cysts in the central portion of their cornea, their vision has [declined] significantly, or they have haze in the center of their cornea, those are definite indications to hold the next treatment. If patients get back to a certain healthy baseline, we can start belantamab mafodotin at either a decreased dose or full dose depending on the patients corneal health.

In the DREAMM-2 study, [investigators] evaluated whether the use of corticosteroids would help in [preventing the] development of these changes. The toxicities associated with a drug are often thought to be related to the inflammation that they induce in a certain tissue.

However, it was found that prophylactic corticosteroid use did not make a difference in the ocular toxicity profile, so that is no longer recommended for patients starting on belantamab mafodotin.

Could you speak to the collaborative efforts required between oncologists and ophthalmologists to manage patients receiving belantamab mafodotin?

One of the really beautiful things about the expanded access protocol, as well as the DREAMM-1 and DREAMM-2 studies and the FDA approval, is that it encourages and requires collaborative management of patients. It is about collaborating with the patient, their oncology team, including the infusion specialist, nurses, pharmacists, and the ophthalmology team.

With the FDA approval, [we have seen] a lot of outreach into the community [regarding this agent and this collaboration]. Community oncologists are going to be prescribing this medication now, so community oncologists and community ophthalmologists [need to be educated on] what these toxicities are, how frequently patients should be screened, and how frequent follow-ups should be. The lines of communication between the ophthalmology team and the oncology team need to be kept open.

What are some of the challenges that remain in this space?

In an academic center, it is much easier to collaborate with other departments. For example, the ophthalmology department is in full collaboration with the oncology department [at Cornell] so that we can get these patients seen quickly and get the [treatment] decision over to the oncology department. Once community doctors are prescribing belantamab mafodotin more, the challenge will be getting patients quickly to an ophthalmologist or having ophthalmologists ready to see these patients. Additionally, making sure that the ophthalmologists are communicating efficiently, quickly, and clearly to the oncology team could become a challenge as well.

What would you like to emphasize regarding the management of ocular toxicities among patients receiving belantamab mafodotin?

The most important thing is to make sure that all parties are equally aware of the importance of communication with one another, as well as communication with the patient. Oftentimes, patients [receiving belantamab mafodotin] may feel like this drug is their last resort. Patients may ignore certain AEs that they are having or may not be aware of what AEs are important [to report]. Keeping those lines of communication open, not just among providers, but with the patient, as well as educating patients on the potential toxicities that could manifest is important. Additionally, making sure that patients follow up with the ophthalmologist, even if they are asymptomatic, is important.

It is a really exciting time because it affords us, as ophthalmologists, the opportunity to collaborate on a truly systemic disease. It is also exciting to be able to be part of a larger treatment team and to work within other specialties.

References:

See the article here:
From the Ophthalmologist's Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma - OncLive

Read More...

Scientists discover genetic and immunologic underpinnings of some cases of severe COVID-19 – National Institutes of Health

September 26th, 2020 5:59 am

Media Advisory

Thursday, September 24, 2020

New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19.

The researchers found that more than 10% of people who develop severe COVID-19 have misguided antibodiesautoantibodiesthat attack the immune system rather than the virus that causes the disease. Another 3.5% or more of people who develop severe COVID-19 carry a specific kind of genetic mutation that impacts immunity. Consequently, both groups lack effective immune responses that depend on type I interferon, a set of 17 proteins crucial for protecting cells and the body from viruses. Whether these proteins have been neutralized by autoantibodies orbecause of a faulty genewere produced in insufficient amounts or induced an inadequate antiviral response, their absence appears to be a commonality among a subgroup of people who suffer from life-threatening COVID-19 pneumonia.

These findings are the first published results from the COVID Human Genetic Effort, an international project spanning more than 50 genetic sequencing hubs and hundreds of hospitals. The effort is co-led by Helen Su, M.D., Ph.D., a senior investigator at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH; and Jean-Laurent Casanova, M.D., Ph.D., head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University in New York. Major contributions were made by Luigi Notarangelo, M.D., chief of the NIAID Laboratory of Clinical Immunology and Microbiology (LCIM); Steven Holland, M.D., director of the NIAID Division of Intramural Research and senior investigator in the NIAID LCIM; clinicians and investigators in hospitals in the Italian cities of Brescia, Monza and Pavia, which were heavily hit by COVID-19; and researchers at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

The wide variation in the severity of disease caused by SARS-CoV-2, the virus behind COVID-19, has puzzled scientists and clinicians. SARS-CoV-2 can cause anything from a symptom-free infection to death, with many different outcomes in between. Since February 2020, Drs. Su and Casanova and their collaborators have enrolled thousands of COVID-19 patients to find out whether a genetic factor drives these disparate clinical outcomes.

The researchers discovered that among nearly 660 people with severe COVID-19, a significant number carried rare genetic variants in 13 genes known to be critical in the bodys defense against influenza virus, and more than 3.5% were completely missing a functioning gene. Further experiments showed that immune cells from those 3.5% did not produce any detectable type I interferons in response to SARS-CoV-2.

Examining nearly 1,000 patients with life-threatening COVID-19 pneumonia, the researchers also found that more than 10% had autoantibodies against interferons at the onset of their infection, and 95% of those patients were men. Biochemical experiments confirmed that the autoantibodies block the activity of interferon type I.

Q Zhang et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science DOI: 10.1126/science.abd4570 (2020).

P Bastard et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science DOI: 10.1126/science.abd4585 (2020).

NIAID Director Anthony S. Fauci, M.D., NIAID Senior Investigator Helen C. Su, M.D., Ph.D., and Luigi Notarangelo, M.D., chief of the NIAID Laboratory of Clinical Immunology and Microbiology, are available for interviews.

To schedule interviews, please contact NIAID Office of Communications, (301) 402-1663, NIAIDNews@niaid.nih.gov.

NIAID conducts and supports research at NIH, throughout the United States, and worldwide to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

View original post here:
Scientists discover genetic and immunologic underpinnings of some cases of severe COVID-19 - National Institutes of Health

Read More...

U of T researchers identify genes that enable cancer to evade the immune system – News@UofT

September 26th, 2020 5:59 am

Researchers at the University of Toronto have mapped the genes that allow cancer cells to avoid being killed by the immune system a finding that paves the way for the development of immunotherapies that could be effective for large patient populations and across different tumour types.

Over the last decade, different forms of immunotherapy have emerged as really potent cancer treatments, but the reality is that they only generate durable responses in a fraction of patients and not for all tumour types, saysJason Moffat, a professor of molecular genetics at the Donnelly Centre for Cellular and Biomolecular Research who led the work.

The study, published inNature, also revealed the need for new therapy to take into account the genetic composition of tumours because of mutations in the cancer cells that can potentially make the disease worse in response to treatment, often referred to as cancer resistance mutations.

Its very important to understand at the molecular level how cancer develops resistance to immunotherapies in order to make them more broadly available, saysMoffat, who holds a Canada Research Chair in Functional Genomics of Cancer.Advances in systematic genetic approaches have let us key in on genes and molecular pathways that are commonly involved in resistance to therapy.

In immunotherapy, a patients own immune cells, known as T killer cells, are engineered to find and destroy cancer. But treatment resistance has precluded its use in most patients, especially those with solid tumours.

Its an ongoing battle between the immune system and cancer, where the immune system is trying to find and kill the cancer whereas the cancers job is to evade that killing, saysKeith Lawson, a co-lead author who iscompleting a PhD in Moffats lab as part of his medical training in the surgeon-scientist program at U of Ts Faculty of Medicine.

Tumour heterogeneity genetic variation in tumour cells within and across individuals that can impact therapy response further complicates treatment.

Its important to not just find genes that can regulate immune evasion in one model of cancer, but what you really want are to find those genes that you can manipulate in cancer cells across many models because those are going to make the best therapeutic targets, Lawson says.

The team, including collaborators from Agios Pharmaceuticals in Cambridge, Mass., looked for genes that regulate immune evasion across six genetically diverse tumor models derived from breast, colon, kidney and skin cancer. The cancer cells were placed in a dish alongside the T cells engineered to kill them, where the ensuing onslaught served as a baseline. The researchers next deployed the gene editing tool CRISPR to switch off one-by-one every gene in the cancer cells and measured the resulting deviations from the killing baseline.

They identified 182 core cancer intrinsic immune evasion genes whose deletion makes the cancer cells either more sensitive or more resistant to T cell attack. Among the resisters were all the genes known to develop mutations in patients who stopped responding to immunotherapy, giving the researchers confidence that their approach worked.

Many of the discovered genes had no previous links to immune evasion.

That was really exciting to see, because it means that our dataset was very rich in new biological information,Lawson says.

Genes involved in autophagy, a process when cells ramp up recycling their components to mitigate damage following stress, came up as key for immune evasion. This raises the possibility that cancers susceptibility to immunotherapy could be boosted by targeting its autophagy genes.

But as the researchers delved deeper, they found that deleting certain autophagy genes in pairs rendered the cells resistant to T cell killing. That means that if a tumour already harbours a mutation in one autophagy gene, a treatment that combines immunotherapy with a drug targeting another autophagy gene could make the disease worse in that patient.

We found this complete inversion of gene dependency,says Moffat. We did not anticipate this at all. What it shows us is that genetic context what mutations are present very much dictates whether the introduction of the second mutationwill cause no effect, resistance or sensitivity to therapy.

As more research explores combinatorial effects of mutations across different types of cancer cells, it should become possible to predict from a tumours DNA what type of therapy will be most effective.

The research was funded by the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research and Agios Pharmaceuticals.

Read more here:
U of T researchers identify genes that enable cancer to evade the immune system - News@UofT

Read More...

Bacterial viperins prove effective against human viruses: Researchers – Express Pharma

September 26th, 2020 5:59 am

Virus-fighting viperins, part of the human immune system, turn out to have bacterial counterparts that might boost the fight against human disease.

By tracking the evolution of what may be our oldest means of fighting off viral infection, a group at the Weizmann Institute of Science has uncovered antiviral substances that may lead to the development of highly effective antiviral drugs. These substances are made by virus-fighting enzymes known as viperins, which were previously known to exist only in mammals, and have now been found in bacteria. The molecules produced by the bacterial viperins are currently undergoing testing against human viruses such as the influenza virus and COVID-19. The study was published in Nature.

Studies conducted over the past decade by Prof Rotem Sorek and his group in the Institutes Molecular Genetics Department, as well as those by other scientists, have revealed that bacteria have highly sophisticated immune systems, despite their microscopic size. In particular, they are equipped to fight off phages viruses that infect bacteria. These differ from the kind that infect humans in their choice of targets, but they all consist of genetic material DNA or RNA that hijacks parts of the hosts replication machinery to make copies of themselves and spread.

Prof Sorek has found that some of these bacterial immune responses suggest evolutionary links to our own immune systems, and the present study in his lab shows the strongest evidence yet: They discovered that viperin antiviral enzymes whose function in the human immune system was understood only two years ago play a role in the immune system of bacteria.

In humans, viperin belongs to the innate immune system, the oldest part of the immune system in terms of evolution. It is produced when a signalling substance called interferon alerts the immune system to the presence of pathogenic viruses. The viperin then releases a special molecule that is able to act against a broad range of viruses with one simple rule: The molecule mimics nucleotides, bits of the genetic material needed to replicate their genomes. But the viperin molecule is fake: It is missing a vital piece that enables the next nucleotide in the growing strand to attach. Once the faux-nucleotide is inserted into the replicating viral genome, replication comes to a halt and the virus dies.

This simplicity and broad action against many different viruses suggested viperins had been around for some time, but could they go back as far as our common ancestors with bacteria? Led by former postdoctoral fellow Dr Aude Bernheim in Soreks lab, the group used techniques that had been developed in his lab to detect bacterial sequences encoding possible viperins. They then showed that these viperins did, indeed, protect bacteria against phage infection.

Whereas the human viperin produces a single kind of antiviral molecule, we found that the bacterial ones generate a surprising variety of molecules, each of which can potentially serve as a new antiviral drug, says Sorek.

Based on the genetic sequences, Sorek and his team were able to trace the evolutionary history of viperins: We found that this important component of our own antiviral immune system originated in the bacterial defence against viruses that infect them, says Sorek.

If the bacterial viperins prove effective against human viruses, Sorek thinks it may pave the way for the discovery of further molecules generated by bacterial immune systems that could be adopted as antiviral drugs for human diseases. As we did decades ago with antibiotics antibacterial substances that were first discovered in fungi and bacteria we might learn how to identify and adopt the antiviral strategies of organisms that have been fighting infection for hundreds of millions of years.

The current study was conducted in collaboration with researchers from Pantheon Biosciences, which has licensed the rights through Yeda Research and Development, the technology transfer arm of the Weizmann Institute of Science, to develop anti-viral drugs based on the findings. Further studies are underway to determine which of the bacterial viperins could be best adapted to fighting human viruses, including, COVID-19. Also participating in this research were Adi Millman, Gal Ofir, Gilad Meitav, Carmel Avraham, Sarah Melamed and Dr Gil Amitai, all of Soreks group in the Weizmann Institute of Sciences Molecular Genetics Department.

Prof Rotem Sorek is Head of the Knell Family Center for Microbiology; his research is also supported by the Willner Family Leadership Institute for the Weizmann Institute of Science; the Sagol Weizmann-MIT Bridge Program; the Schwartz/Reisman Collaborative Science Program; the Ben B and Joyce E Eisenberg Foundation; the Yotam Project; and the European Research Council.

View post:
Bacterial viperins prove effective against human viruses: Researchers - Express Pharma

Read More...

Virus-Fighting Enzymes in Bacteria Could Lead to Development of Highly Effective Antiviral Drugs Against COVID-19 – HospiMedica

September 26th, 2020 5:59 am

Image: The viperins in bacteria have evolved to fight a variety of viruses (Photo courtesy of Weizmann Institute of Science)

A group of scientists at the Molecular Genetics Department at the Weizmann Institute of Science (Rehovot, Israel) has uncovered a gold mine of antiviral substances made by virus-fighting enzymes known as viperins. The molecules produced by the bacterial viperins are currently undergoing testing against human viruses such as the influenza virus and COVID-19.

Earlier studies conducted by the group as well as other scientists have revealed that bacteria have highly sophisticated immune systems, despite their microscopic size. In particular, they are equipped to fight off phages - viruses that infect bacteria. These differ from the kind that infect humans in their choice of targets, but they all consist of genetic material - DNA or RNA - that hijacks parts of the hosts replication machinery to make copies of themselves and spread.

The group of scientists have now found that some of these bacterial immune responses suggest evolutionary links to our own immune systems, and the present study in their lab shows the strongest evidence yet: They discovered that viperin antiviral enzymes - whose function in the human immune system was understood only two years ago - play a role in the immune system of bacteria.

In humans, viperin belongs to the innate immune system, the oldest part of the immune system in terms of evolution. It is produced when a signaling substance called interferon alerts the immune system to the presence of pathogenic viruses. The viperin then releases a special molecule that is able to act against a broad range of viruses with one simple rule: The molecule mimics nucleotides, bits of genetic material needed to replicate their genomes. But the viperin molecule is fake: It is missing a vital piece that enables the next nucleotide in the growing strand to attach. Once the faux-nucleotide is inserted into the replicating viral genome, replication comes to a halt and the virus dies.

This simplicity and broad action against many different viruses suggested viperins had been around for some time, but could they go back as far as our common ancestors with bacteria? The group used techniques that had been developed in their lab to detect bacterial sequences encoding possible viperins. They then showed that these viperins did, indeed, protect bacteria against phage infection. Based on the genetic sequences, the team was able to trace the evolutionary history of viperins. If the bacterial viperins prove effective against human viruses, then it may pave the way for the discovery of further molecules generated by bacterial immune systems that could be adopted as antiviral drugs for human diseases. Further studies are underway to determine which of the bacterial viperins could be best adapted to fighting human viruses, including, of course, COVID-19.

As we did decades ago with antibiotics - antibacterial substances that were first discovered in fungi and bacteria - we might learn how to identify and adopt the antiviral strategies of organisms that have been fighting infection for hundreds of millions of years, said Prof. Rotem Sorek from the Institutes Molecular Genetics Department.

Related Links:Weizmann Institute of Science

Go here to see the original:
Virus-Fighting Enzymes in Bacteria Could Lead to Development of Highly Effective Antiviral Drugs Against COVID-19 - HospiMedica

Read More...

Molecular Diagnostics Market Incredible Possibilities, Growth Analysis and Forecast To 2025 – The Daily Chronicle

September 26th, 2020 5:59 am

Molecular diagnostics is a way of performing a diagnostic test to discover ailment, circumstance or infection in an artificial surroundings. Molecular diagnostic is one of the principal segments of in-vitro diagnostics marketplace. Molecular diagnostics is used to measure and stumble on the presence of genetic fabric related to specific disorder. It is used to identify DNA and RNA at molecular stage. Molecular diagnostics is a device to improve clinical effects and clinical decisions. Molecular diagnostic consists of all exams used to become aware of a disorder, by analyzing molecules such as DNA, protein or RNA in a fluid or tissue. In recent times molecular diagnostics is utilized in early detection of infectious sicknesses, most cancers and genetic ailment, by way of the usage of molecular and genetic technologies. Molecular diagnostics is likewise utilized in detection of abnormalities in pre-natal stage. Further, molecular diagnostic kits are utilized in pharmacogenetics trying out and blood donor screening.

The Global Molecular Diagnostics Market is expected to exceed more than US$ 12.50 billion by 2024 and will grow at a CAGR of more than 8.5% in the given forecast period.

You Can Browse Full Report @: https://www.marketresearchengine.com/reportdetails/molecular-diagnostics-market

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Roche Diagnostics (U.S.), QIAGEN N.V. (Netherlands), Hologic Inc. (U.S.), Grifols (Spain), Abbott Laboratories (U.S.), Siemens Healthcare (Germany), Becton, Dickinson and Company (U.S.), Beckman Coulter Inc. (U.S.), bioMrieux SA (France), and Cepheid Inc. (U.S.). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The molecular diagnostics market is segmented by product, by technology, by application and by end user analysis. Under the product and service segmentation it contains instruments, reagents and services & software. It uses different technologies such as polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA sequencing and next-generation sequencing, microarrays, mass pectrometry, flow cytometry, and electrophoresis. Molecular diagnostics techniques are used in different application such as infectious diseases, oncology, genetics, blood screening, microbiology, cardiovascular diseases, neurological diseases, and DNA fingerprinting. The end user of molecular diagnostics are reference laboratories, hospital laboratories, blood banks, local public health laboratories, home health agencies, nursing homes, point-of-care settings, and self-testing. The molecular diagnostics market is geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

The scope of the report includes a detailed study of global and regional markets for various types of molecular diagnostics market with the reasons given for variations in the growth of the industry in certain regions.

The Molecular diagnostics Market has been segmented as below:

The Molecular diagnostics Market is Segmented on the lines of Application Analysis, Product and service Segment Analysis, Technology Analysis, End-user Analysis and Regional Analysis. By Application Analysis this market is segmented on the basis of Infectious Diseases, Oncology, Genetics, Blood Screening, Microbiology and Others (Cardiovascular Diseases, Neurological Diseases, and DNA Fingerprinting). By Product and service Segment Analysis this market is segmented on the basis of Instruments, Reagents and Services & Software.

By Technology Analysis this market is segmented on the basis of Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Hybridization, DNA Sequencing and Next-generation Sequencing, Microarrays and Others (Mass Spectrometry, Flow Cytometry, and Electrophoresis). By End-user Analysis this market is segmented on the basis of Reference Laboratories sector, Hospital Laboratories sector and Others (Blood Banks, Local Public Health Laboratories, Home Health Agencies, Nursing Homes, Point-of-care Settings, and Self-testing) sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

The major driving factors of Global Molecular Diagnostics Market are as follows: Increasing application in blood screening Increasing prevalence of chronic and infectious diseases such as HIV and hepatitis Rising awareness and acceptance of personalized medicine

The restraining factors of Global Molecular Diagnostics Market are as follows:

Require more time for approval of many new molecular diagnostic tests Changing reimbursement regulations

This report provides:1) An overview of the Global Molecular Diagnostics Market and related technologies.2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.3) Identifications of new market opportunities and targeted promotional plans for Global Molecular Diagnostics Market.4) Discussion of research and development, and the demand for new products and new applications.5) Comprehensive company profiles of major players in the industry.

Reasons to Buy this Report:1) Obtain the most up to date information available on all Global Molecular Diagnostics Market.2) Identify growth segments and opportunities in the industry.3) Facilitate decision making on the basis of strong historic and forecast of Global Molecular Diagnostics Market data.4) Assess your competitors refining portfolio and its evolution.

Request Sample Report from here: https://www.marketresearchengine.com/reportdetails/molecular-diagnostics-market

Table of Contents

1 INTRODUCTION

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Molecular Diagnostics Market Overview

6 Molecular Diagnostics Market, By Application

7 Molecular Diagnostics Market, By Technology

8 Molecular Diagnostics Market, By Products and Services

8.1 Introduction8.2 Reagents & Kits8.3 Instruments8.4 Software & Services

9 Molecular Diagnostics Market, By End User

10 Molecular Diagnostics Market, By Region

11 Competitive Landscape

12 Company Profiles

12.1 Introduction

12.2 Abbott Laboratories

12.3 Qiagen N.V.

12.4 Roche Diagnostics

12.5 Hologic, Inc.

12.6 Grifols

12.7 Siemens Healthcare

12.8 Becton, Dickinson and Company

12.9 Beckman Coulter Inc. (A Wholly Owned Subsidiary of Danaher Corporation)

12.10 Biomrieux Sa

12.11 Cepheid Inc.

Other Related Market Research Reports:

Minimally Invasive Medical Robotics Market is Determined to Cross US$ 44 Billion by 2022

Medical Tourism Market is Projected to Reach US$ 54.00 Billion by 2022

Medical Waste Management Market is Supposed to Reach US$ 21.00 Billion by 2024

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

View original post here:
Molecular Diagnostics Market Incredible Possibilities, Growth Analysis and Forecast To 2025 - The Daily Chronicle

Read More...

Page 371«..1020..370371372373..380390..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick